Search 

There is a high unmet need for central nervous system (CNS) diseases in the growing aging population. Chronic inflammation is associated with a broad spectrum of neurodegenerative diseases related to aging. Genervon is bringing GM6, a new clinical-stage drug asset, to regulatory approval and commercialization in China for CNS diseases including Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), Multiple Sclerosis (MS), and other neurodegenerative diseases. Most clinical trials for drugs developed through the traditional single-target drug approach have failed to treat the complex neurological disorders that involve multiple interrelated pathways.

GM6 is an innovative first-in-class regulator peptide drug in clinical stage. Genervon Biopharmaceuticals discovered an endogenous embryonic-stage regulator, Motoneuronotrophic Factor (MNTF), and developed from it the pleiotropic drug GM6. GM6 is neither an antibody nor a single-target agonist or antagonist. It is a multi-target regulator which simultaneously acts upon multiple extracellular receptors to modulate a series of signaling pathways mediating inflammation and pro-survival responses in both CNS and immune system. Genervon has validated GM6’s target engagement of multiple targets and druggability. GM6 has been de-risked for toxicity in animal studies and safety in three clinical trials. IND documents filed with the FDA can be used to support regulatory filing in China for clinical trials. Genervon is interested to partner through licensing or merger and acquisition. A complete CMC package is ready for technology transfer.

A clinical-stage US pharma company with a P2B asset (US FDA IND) targeted for multiple substance use disorders and stressor-related disorders (e.g., PTSD) with unmet medical needs.

Genova Inc., a bio-pharma company dedicated in the innovation of better protein-drugs for viral diseases, cancer and auto-immune diseases. Novaferon ，the first novel protein drug of Genova, shows antiviral efficacy on viral clearance in a proof of concept randomized clinical trial and approved by Healthcare Canada and PMDA of Japan entering into phase 3 multinational centers clinical trial in last December. We are right looking for strategic parthership with big pharma. Contact: ctxu@genova.cn

Each of the above biopolymer "viscous fluid implants" are also ideal drug delivery media for treatment of ancillary complications. All component biopolymers are well documented APIs, i.e. without the toxicty and other regulatory issues generally associated with "New Chemical Entities". Glenpharma´s current patent protection covers most major international markets including USA, Europe and P R China. Glenpharma is primarily seeking Chinese partners for Licensing-out within the fields of orthopedics or major surgery.. If neccessary , we can offer contract-manufacturing options in Europe if not available in China.;